The Opdivo/Yervoy combination demonstrated statistically and clinically significant improvements in the Phase III ...
Exscientia paid $20m in upfront cash and equity to buy its development partner GT Apeiron’s shares for the CDK7 inhibitor.
New global projections and advances in HIV therapies are also on the agenda at the 25th International AIDS 2024 meeting.
The US FDA has accepted the BLA and granted priority review for Pierre Fabre Pharmaceuticals’ Tabelecleucel to treat EBV+ ...
Boehringer Ingelheim is a key player in the Humira biosimilars market. Image credit: Shutterstock / Tada Images. Boehringer ...
Rona Therapeutics has secured $35m in its Series A+ financing round to advance its metabolic siRNA pipeline in clinical ...
The EMA has accepted the MAA of Deciphera Pharmaceuticals' vimseltinib to treat tenosynovial giant cell tumours for review.
Meitheal Pharmaceuticals has gained rights to CONTEPO (fosfomycin for injection) from Nabriva Therapeutics for the North ...
Entrepeneur Sean Parker, who established the Parker Institute, speaking at the Philly Fights Cancer event in November 2018 in ...
AbbVie is set to expand the indication list for its immunology blockbuster, Rinvoq (upadacitinib). The company has submitted ...
LOTTE BIOLOGICS’ Songdo Bio Campus in Incheon, South Korea includes the development of three biomanufacturing facilities by 2030. LOTTE BIOLOGICS is building the new Songdo Bio Campus in Incheon, ...
CytoReason has secured $80m in funding from a consortium of investors to enhance its AI disease models. The investors are ...